![Rank: 8](static/image/common/star_level3.gif) ![Rank: 8](static/image/common/star_level3.gif)
- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
The Liver Meeting® 2014
The Next Generation of HBV Therapy: From Discovery to Cure
Organizers: T. Jake Liang, MD and Prof. Timothy M. Block
Content contributors:
Hepatitis B SIG
Monday, November 10, 2014;
4:45pm–7:50 pm
Chronic hepatitis B infection is associated with a significant risk of liver cirrhosis (LC) and hepatocellular carcinoma (HCC). There are now 7 approved medications to manage chronic hepatitis B, but these require indefinite periods of use, are not indicated for all chronic hepatitis B patients. Moreover, as currently used, these medications reduce the risk of death due to liver disease by only 50- 60% after ten years of use. There is therefore a great interest in the professional community in the understanding and knowing about new therapeutics that complement or improve upon the current portfolio. Management patients with chronic hepatitis B and the discovery of new liver disease therapies is a centrally responsive to the AASLD mission.
This Single Interest Group (SIG) session will address these issues through colloquia.
Learning Objectives:
•Predict the next wave of HBV therapeutics.
•Employ hepatitis research programs in response to the information communicated at the meeting and stimulate interest in collaborative studies.
•Discuss the status of new HBV drugs in the development pipeline.
4:45–4:50pm
Introduction
T. Jake Liang, MD and Timothy M. Block, D
4:50–5:05pm
Currently Approved Hepatitis B Therapeutics: Their Indications and Limitations
Brian J. McMahon, MD
5:05–5:15pm
Does combination therapy of interferon and nucleoside analogs make sense?
Mark Ghany, MD
Session I: Direct Acting Antiviral Therapies
Moderators:
Raymond F Schinazi, PhD
and Robert G. Gish, MD
5:15–5:30pm
Entry Inhibitors: Myrcludex and Cyclosporins
Stephan Urban, PhD
5:30–5:45pm
Eradication of cccDNA by small molecules
JuTao Guo, MD
5:45–6:00pm
Assembly inhibitors
Stephen Locarnini, MD, PhD
6:00–6:20pm
Panel Discussion and Audience Comments/Questions
6:20–6:30pm
Break
Session II: Indirect Acting Agents
Moderators: Eugene R. Schiff, MD and Patrick Marcellin, MD, PhD
6:30–6:45pm
Eradication of cccDNA by Immune modulators
T. Jake Liang, MD
6:45–7:00pm
Toll-like receptor, PD1 and Other Immune Modulators
Fabien Zoulim, MD
7:00–7:15pm
Therapeutic vaccines, siRNA, Other Nucleic Acid-based Technologies
Kyong-Mi Chang, MD
7:15–7:35pm
Panel Discussion and Audience Comments/Questions
7:35–7:50pm
Summary: Anna S. F. Lok, MD
|
|